Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer

Urology

Volumn 68, Issue 2, 2006, Pages 371-375

  Kikuchi, Eiji ^a   Nakashima, Jun ^a   Ishibashi, Midori ^a   Ohigashi, Takashi ^a   Oya, Mototsugu ^a   Nakagawa, Ken ^a   Miyajima, Akira ^a   Murai, Masaru ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN; MULTIPROTEIN COMPLEX;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER SCREENING; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; BONE TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; ALPHA 1-ANTICHYMOTRYPSIN; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33746838545     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.02.031     Document Type: Article

References (17)

1. Levran Z., Gonzalez J.A., Diokno A.C., et al. Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer?. Br J Urol 75 (1995) 778-781
2. Gleave M.E., Coupland D., Drachenberg D., et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 47 (1996) 708-712
3. Wolff J.M., Bares R., Jung P.K., et al. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. Urol Int 56 (1996) 169-173
4. Chybowski F.M., Keller J.J., Bergstralh E.J., et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer. prostate specific antigen is superior to all other clinical parameters. J Urol 145 (1991) 313-318
5. Wu J.T., and Liu G.H. Advantages of replacing the total PSA assay with the assay for PSA-alpha 1-antichymotrypsin complex for the screening and management of prostate cancer. J Clin Lab Anal 12 (1998) 32-40
6. Kikuchi E., Nakashima J., Ishibashi M., et al. Prostate specific antigen adjusted for transition zone volume. the most powerful method for detecting prostate carcinoma. Cancer 89 (2000) 842-849
7. Horinaga M., Nakashima J., Ishibashi M., et al. Clinical value of prostate specific antigen based parameters for the detection of prostate cancer on repeat biopsy. the usefulness of complexed prostate specific antigen adjusted for transition zone volume. J Urol 168 (2002) 986-990
8. Partin A.W., Brawer M.K., Bartsch G., et al. Complexed prostate specific antigen improves specificity for prostate cancer detection. results of a prospective multicenter clinical trial. J Urol 170 (2003) 1787-1791
9. 1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL. BJU Int 95 (2005) 761-765
10. 1-antichymotrypsin complex values in diagnosis of prostate cancer. a cooperative study. Int J Urol 5 (1998) 48-54
11. Taneja S.S., Hsu E.I., Cheli C.D., et al. Complexed prostate-specific antigen as a staging tool. results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. Urology 60 (2002) 10-17
12. Hara I., Miyake H., Hara S., et al. Significance of prostate-specific antigen-alpha(1)-antichymotrypsin complex for diagnosis and staging of prostate cancer. Jpn J Clin Oncol 31 (2001) 506-509
13. Soloway M.S., Hardeman S.W., Hickey D., et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 (1988) 195-202
14. Hanley J.A., and McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982) 29-36
15. Horninger W., Cheli C.D., Babaian R.J., et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology 60 (2002) 31-35
16. Bruwer G., Heyns C.F., and Allen F.J. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. Eur Urol 35 (1999) 223-227
17. Oesterling J.E., Martin S.K., Bergstralh E.J., et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269 (1993) 57-60